Recombinant Human VEGF coregulated chemokine 1 protein (CXCL17) is produced in E. coli and represents the full length of the mature protein, spanning amino acids 22-119. This tag-free protein achieves a purity greater than 96% as confirmed by SDS-PAGE analysis. The protein demonstrates full biological activity, inducing VEGF expression with an ED50 of less than 5.0 μg/ml in murine endothelial cells, which corresponds to a specific activity greater than 200 IU/mg. Endotoxin levels remain controlled at less than 1.0 EU/μg, as measured by the LAL method.
CXCL17 appears to play an important role in immune cell recruitment and helps modulate inflammatory responses. The protein seems particularly relevant for angiogenesis regulation through its capacity to induce VEGF expression. This makes CXCL17 an intriguing target for vascular biology research, though our understanding of its complete functional network may still be developing. Researchers studying immune response and tissue repair mechanisms likely need to consider CXCL17's function and interactions.
Potential Applications
Note: The applications listed below are based on what we know about this protein's biological functions, published research, and experience from experts in the field. However, we haven't fully tested all of these applications ourselves yet. We'd recommend running some preliminary tests first to make sure they work for your specific research goals.
1. VEGF Expression Induction Assays
This recombinant CXCL17 protein is confirmed to be biologically active in inducing VEGF expression in murine endothelial cells (ED₅₀ < 5.0 μg/ml) and can be used for related studies. However, the relatively high ED₅₀ value (compared to typical chemokines with ng/ml range activity) suggests lower potency, requiring higher concentrations for effective stimulation. Researchers should perform careful dose optimization in their specific endothelial cell models. The high purity (>96%) and low endotoxin support reliable results, but the modest specific activity (>200 IU/mg) indicates this protein may have limited functional potency.
2. Chemokine Receptor Binding Studies
While the protein is biologically active, CXCL17's cognate receptor remains unidentified in the scientific literature, making receptor-binding studies highly exploratory. The tag-free design is advantageous, but without a known receptor target, binding assays would be speculative. Researchers should first confirm CXCL17-receptor interactions using positive controls before undertaking detailed binding characterization. The high ED₅₀ may reflect low receptor affinity or alternative signaling mechanisms.
3. Angiogenesis Research Models
The demonstrated VEGF induction activity supports using this CXCL17 in angiogenesis assays, but researchers should note that the high working concentrations (μg/ml range) may cause non-specific effects in sensitive assays like tube formation. Include appropriate controls to distinguish specific CXCL17 effects from potential non-specific stimulation. The modest specific activity suggests using this protein primarily for qualitative rather than quantitative angiogenesis studies.
4. Antibody Development and Validation
The high purity and confirmed bioactivity make this protein suitable for antibody development. However, the low specific activity may challenge neutralization assays, as high antibody concentrations may be needed to block function. Antibodies should be validated for their ability to inhibit VEGF induction in the same murine endothelial cell system used for activity testing to ensure functional relevance.
5. Protein-Protein Interaction Studies
This CXCL17 can be used for interaction studies, but the unknown receptor identity limits directed approaches. Interaction screening should be broad (e.g., proteomic approaches) rather than targeted. The high ED₅₀ may indicate weak interactions that require sensitive detection methods. Any identified binding partners need validation in physiological contexts to establish biological relevance.
Final Recommendation & Action Plan
This recombinant human CXCL17 has confirmed VEGF-inducing activity but exhibits relatively low potency (high ED₅₀) and specific activity compared to typical chemokines. Prioritize its use in VEGF induction and angiogenesis studies where activity has been demonstrated, using concentrations in the 1-10 μg/ml range with appropriate vehicle controls. For receptor and interaction studies, acknowledge the preliminary nature of current CXCL17 receptor knowledge and employ unbiased screening approaches. When developing antibodies, focus on applications requiring detection rather than neutralization due to the protein's low functional potency. Always include rigorous controls to account for potential non-specific effects at the required high concentrations. Consider confirming key findings with multiple lots or expression systems to ensure results are not specific to this preparation.
